Haleon PLC Sponsored ADR ( (HLN) ) has shared an update.
On April 11, 2025, Haleon PLC announced the purchase of 902,692 ordinary shares for cancellation as part of its share buyback program initiated on March 28, 2025. This transaction is expected to impact the company’s share capital and voting rights, with the registered share capital now standing at 9,031,310,069 ordinary shares, of which 4,080,205 are held as treasury shares. The buyback reflects Haleon’s strategic financial management and may influence shareholder interests in line with the FCA’s Disclosure Guidance and Transparency Rules.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.
Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Haleon is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are built on a foundation of science, innovation, and deep human understanding.
YTD Price Performance: 2.01%
Average Trading Volume: 11,401,954
Technical Sentiment Signal: Sell
Current Market Cap: $42B
Learn more about HLN stock on TipRanks’ Stock Analysis page.